# #

Free Download:

The Complete n-of-1 Strategy Guide & Toolkit

Your N-of-1 Strategy Toolkits

FDA Guidance & Highlights, annotated for ultra-rare developers

FDA Guidance & Highlights, annotated for ultra-rare developers

A focused FDA guidance package with highlights and annotations for ultra-rare developers planning an N-of-1 strategy.

more
  • 1-1 FDA Highlights.pdf
  • 1-2 FDA Guidance: CMC Flexibilities for CGT BLA - May2026.pdf
  • 1-3 FDA Guidance: FAQs-Developing Potential CGT Products-Aug2026.pdf
  • 1-4 FDA Guidance: Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions - Feb2026.pdf
Annotated FDA guidance set for ultra-rare developers, designed to support faster review of CGT strategy, CMC positioning, and individualized therapy considerations.
CDMO readiness checklist

CDMO readiness checklist

A practical checklist to help you assess whether a CDMO can support the technical, regulatory, and operational needs of an N-of-1 program.

more
Use this checklist to compare partner capabilities across process readiness, analytical depth, documentation support, and program cadence.
Budget template: 1-batch vs 3-batch scenario

Budget template: 1-batch vs 3-batch scenario

A side-by-side budget model for comparing a single-batch strategy against a conventional three-batch approach for an N-of-1 program.

more
This spreadsheet helps teams compare total cost, timing, and scenario assumptions while keeping the N-of-1 plan easy to explain internally.
China IIT Guide

China IIT Guide

A guide to the China IIT pathway, with supporting materials for teams exploring earlier clinical access opportunities.

more
  • 4-1 IIT solution brochure.pdf
  • 4-2 CoJourney total solution for China IIT.pdf
The guide pairs practical pathway context with a broader solution overview for teams evaluating IIT strategy and local execution.